SECsense Logo

Xenon Pharmaceuticals Inc. 8-K Report: Key Corporate Update on January 17, 2025

$XENE
Form 8-K
Filed on: 2025-01-17
Source
Xenon Pharmaceuticals Inc. 8-K Report: Key Corporate Update on January 17, 2025

From the provided section of the financial report, the following key information can be extracted:

  1. Entity Information:
  • Company Name: Xenon Pharmaceuticals Inc.
  • CIK: 0001582313
  • Address: 3650 Gilmore Way, Burnaby, BC, CA, V5G 4W8
  • Phone Number: 604 484-3300
  • Stock Ticker: XENE
  • Exchange: NASDAQ
  1. Filing Information:
  • Filing Type: Form 8-K
  • Filing Date: January 17, 2025
  1. Securities Information:
  • Securities Type: Common Shares, without par value
  • SEC File Number: 001-36687
  • IRS Employer Identification Number (EIN): 98-0661854
  1. Reporting Period:
  • Start Date of Reporting Period: January 17, 2025
  • End Date of Reporting Period: January 17, 2025

Insights:

  • The report indicates a specific event or information that necessitated the filing of an 8-K, which is typically used to report unscheduled material events or corporate changes.
  • The reporting period is a single day, which may imply that the filing is related to an event that occurred on that date, such as a significant corporate announcement or decision.
  • The details of the securities (common shares, without par value) suggest that the company may be involved in activities that affect their equity structure, but further context would be needed to understand the implications fully.
  • The inclusion of the company's CIK and IRS EIN facilitates regulatory identification and compliance tracking.

Overall, this filing indicates that Xenon Pharmaceuticals Inc. communicated a significant event to the SEC on January 17, 2025. Further details from the complete filing would be necessary to understand the specific nature and impact of the event reported.